| Provides long-term gene expression by integrating into the host genome |
|
Risk of disrupting genes, potentially causing cancer |
102
|
| Can deliver genes into both dividing and non-dividing cells with long-term expression |
|
Risk of insertional mutagenesis and potential immune responses |
103
|
| Low immunogenicity and stable long-term expression |
|
Limited transgene capacity compared to other viral vectors |
104
|
| High specificity for bacterial targets, making them useful for treating bacterial infections |
|
Limited effectiveness in eukaryotic cells, restricting their use in gene therapy for human cells |
105
|
| Can encapsulate both hydrophilic and hydrophobic drugs, improving drug solubility and stability |
|
Prone to rapid clearance by the immune system, limiting circulation time |
106
|
| High surface area allows for versatile drug loading and targeted delivery |
|
Potential toxicity and accumulation in tissues, raising safety concerns |
107
|
| Enhances the solubility of poorly water-soluble drugs, improving bioavailability |
|
Potential instability in the bloodstream, leading to premature drug release |
108
|
| Naturally derived, making them biocompatible and less likely to trigger immune responses |
|
Challenges in large-scale production and standardization for therapeutic use |
109
|
| High drug-loading capacity and ability to penetrate cells efficiently |
|
Potential toxicity and difficulty in biodegradation, raising safety concerns |
110
|
| Highly branched structure allows for precise drug delivery and targeting capabilities |
|
High production costs and potential toxicity due to their size and surface chemistry |
111
|
| Provides a supportive framework for cell growth and tissue regeneration, mimicking natural extracellular matrices |
|
Complex fabrication processes and potential issues with biocompatibility and integration into surrounding tissues |
112
|
| Provides controlled and sustained drug release, enhancing therapeutic efficiency |
|
Potential for limited drug loading capacity and challenges in large-scale production |
113
|
